Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same
AssigneeHiberCell, Inc.
InventorsRuiping WANG, Meiting SHI, Travis HOUSTON
Life of this patent
Estimating the term…
Abstract
Provided herein are crystalline forms of a compound of formula (I) and pharmaceutical compositions thereof. Also provided herein are methods of using the crystalline forms and pharmaceutical compositions to treat a cancer and viruses (e.g., coronaviruses), and other diseases and disorders involving protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).
Claims118
A fumarate salt of a compound of formula (I)
A crystalline fumarate salt of a compound of formula (I)
A crystalline mono-fumarate salt of a compound of formula (I)
Form A of a mono-fumarate salt of a compound of formula (I)
Form B of a mono-fumarate salt of a compound of formula (I)
Form C of a mono-fumarate salt of a compound of formula (I)
A crystalline hemi-fumarate salt of a compound of formula (I)
Form A of a hemi-fumarate salt of a compound of formula (I)
Form B of a hemi-fumarate salt of a compound of formula (I)
A pharmaceutical composition comprising:
- (i) a fumarate salt of a compound of formula (I)
- and
- (ii) a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising:
- (i) a crystalline fumarate salt of a compound of formula (I)
- and
- (ii) a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising:
- (i) a crystalline mono-fumarate salt of a compound of formula (I)
- and
- (ii) a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising:
- (i) a crystalline hemi-fumarate salt of a compound of formula (I)
- and
- (ii) a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.